Ann Marie Salapatek
- Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamberBy Veit J. Erpenbeck, Ann Marie Salapatek, Piyush Patel, Johanne Sanni, Gerald Dubois, Ping Zhou, Sheryl Perry and Michael LarbigVeit J. Erpenbeck1Primary Care, Novartis Pharma AG, Basel, SwitzerlandAnn Marie Salapatek2Clinical Research, Inflamax Research Inc., Toronto, ON, CanadaPiyush Patel2Clinical Research, Inflamax Research Inc., Toronto, ON, CanadaJohanne Sanni3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomGerald Dubois3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomPing Zhou3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomSheryl Perry3Primary Care, Novartis Pharmaceuticals UK Limited, Horsham, West Sussex, United KingdomMichael Larbig1Primary Care, Novartis Pharma AG, Basel, Switzerland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.